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Abstract
Objective To investigate whether a single optimal vaccination strategy
exists across countries to deal with a future influenza pandemic by
comparing the cost effectiveness of different strategies in various
pandemic scenarios for three European countries.
Design Economic and epidemic modelling study.
Settings General populations in Germany, the Netherlands, and the
United Kingdom.
Data sources Country specific patterns of social contact and
demographic data.
Model An age structured susceptible-exposed-infected-recovered
transmission model that describes how an influenza A virus will spread
in the populations of Germany, the Netherlands, and the United Kingdom.
InterventionsComparison of four vaccination strategies: no vaccination,
blanket vaccination, vaccination of elderly people (≥65 years), and
vaccination of high transmitters (5-19 years). The four strategies were
evaluated for scenarios in which a vaccine became available early or at
the peak of the pandemic, and in which either everyone was initially
susceptible or older age groups had pre-existing immunity.
Main outcome measure Cost per quality adjusted life years (QALYs)
gained.
Results All vaccination strategies were cost effective (incremental cost
per QALY gained, comparing intervention with non-intervention). In
scenarios where the vaccine became available at the peak of the
pandemic and there was pre-existing immunity among elderly people
the incremental cost effectiveness ratios for vaccinating high transmitters
were €7325 (£5815; $10 470) per QALY gained for Germany, €10 216
per QALY gained for the Netherlands, and €7280 per QALY gained for
the United Kingdom. The most cost effective strategy not only differed
across the pandemic scenarios but also between countries. Specifically,
when the vaccine was available early in the pandemic and there was
no pre-existing immunity, in Germany it would be most cost effective to
vaccinate elderly people ( €940 per QALY gained), whereas it would be
most cost effective to vaccinate high transmitters in both the Netherlands
(€525 per QALY gained) and the United Kingdom (€163 per QALY
gained). This difference in optimal strategies was due to differences in
the demographic characteristics of the countries: Germany has a
significantly higher proportion of elderly people compared with the
Netherlands and the United Kingdom.
Conclusions No single vaccination strategy was most cost effective
across countries. With aging populations, pre-existing immunity in
particular could be of crucial importance for the cost effectiveness of
options to mitigate a future influenza pandemic.
Introduction
Many countries have preparedness plans specifying how to deal
with an influenza pandemic and in particular how to prioritise
vaccination if the supply of vaccine falls short. For a small
number of countries the proposed interventions in these plans
have been tested in computer simulations using dynamic
epidemiological models.1-6 For an even smaller number, the cost
effectiveness of the proposed interventions has been analysed.7-9
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Most countries adapt their plans from other countries or follow
general advice from intergovernmental organisations such as
the World Health Organization and the European Centre for
Disease Prevention and Control. These organisations provide
a wide range of countries with general advice on whether to
vaccinate. Yet countries differ in their demographic
characteristics, patterns of social contact, healthcare systems,
and the cost structure of such systems. This raises the question
of whether guidance should be tailored to the national level
instead of providing a single recommendation supposedly
suitable for a range of countries.
Vaccines against pandemic influenza can be produced, albeit
in limited quantities, within a few months after isolation of the
novel pandemic influenza strain. As the capacity for global
production is limited, vaccine would be scarce. If a government
wanted to purchase vaccine it would have to negotiate a contract
with the manufacturers in the initial phase of the pandemic. A
government would thus need to decide early on whether to
purchase vaccines, the number of doses needed, and when to
vaccinate. On the positive side, governments would have enough
time between purchase and delivery to set up the infrastructure
for a vaccination campaign. On the negative side, governments
would need to make important decisions in the absence of
accurate information and thus would need to allow for a variety
of scenarios.
As a result of the scarcity of pandemic vaccines, decisions on
how to allocate these vaccines optimally is important. When
the economic impact of an influenza pandemic is included in
the decision process, country specific details can be of great
significance. Country specific demographic variables and
patterns of social contact affect the transmission of influenza
and may result in differences between the cost effectiveness of
vaccines for countries with different demographic profiles. For
example, in countries with a high percentage of older people
without pre-existing immunity against a new influenza A virus
strain it might be optimal to vaccinate just elderly people,
whereas in countries with a low percentage of older people it
might be optimal to vaccine young people, irrespective of the
presence of pre-existing immunity in the population. If such
situations are common, any general advice on a single best
vaccination strategy might lose its importance.
We investigated whether a single vaccination strategy would
be most cost effective in a range of different pandemic scenarios
for different countries, which age group should be vaccinated
to get the highest benefit from the resources spent, and whether
different strategies apply in different countries. In particular we
investigated the cost effectiveness of vaccination strategies in
different pandemic scenarios for Germany, the Netherlands,
and the United Kingdom; three countries that are geographically
close and culturally similar but differ in their population
structure.
Methods
We linked an age structured transmission model of pandemic
influenza with healthcare consumption and unit costs for
healthcare resources specific to Germany, the Netherlands, and
the United Kingdom. This model incorporates demographic
structures, distinguishes between groups at low and high risk
for developing serious disease, and uses social contact patterns
as a proxy for at risk contacts. The use of a dynamic model is
essential as it enabled us to assess not only the direct effect of
vaccination on those who are vaccinated (as in standard static
models) but also the indirect effect because people who are not
vaccinated are placed at a lower risk of infection.
Model
Transmission model
We used a deterministic age structured
susceptible-exposed-infected-recovered epidemic model that
describes how an influenza A virus would spread in a
population.2 People were categorised into six age groups,
preschool children (0-4 years), primary school children (5-12
years), secondary school children (13-19 years), young adults
(20-39 years), older adults (40-64 years), and elderly people
(≥65 years), and classified as susceptible to infection, infected
but not yet infectious, infected and infectious, or recovered,
immune, or dead. The duration of the infection cycle was set to
match an observed duration of the mean generation interval of
2.8 days for seasonal influenza10 and the novel pandemic
A/H1N1 2009 influenza virus.11 This duration was obtained by
setting the mean latent period at 1.95 days with a variance of
0.48 and by setting the mean infectious period at 1.6 days with
a variance of 0.32.We calibrated the transmissibility of the virus
to render an overall basic reproduction ratio of 1.7 in a
susceptible population, which is in line with epidemic growth
rates observed in past influenza pandemics.10 As the typical
timescale of an influenza pandemic wave is in the order of
months, we did not include effects of changing demographics
during the pandemic, such as aging and births, and deaths due
to reasons other than influenza infection.
Social contact patterns
We calculated age specific contact patterns from data on self
reported social contact rates for Germany, the Netherlands, and
the United Kingdom in 2006.12 Such contacts were aggregated
into the six age groups with similar contact characteristics. A
summary of the contact rates for the six age categories shows
that for all three countries, people tend to mix within their own
age group (see supplementary table A.1).
Demographic data
We set the population size by age group as that for 2006, as
obtained from official sources: Federal Statistical Office for
Germany, Statistics Netherlands, and UK National Statistics
(table 1⇓).
Low and high risk groups
We divided each age group into two subgroups, one with people
at relatively low risk and one with people at high risk of
developing serious complications on infection. High risk groups
included people who were immunocompromised, those with
chronic respiratory diseases, and those aged over 65 in nursing
homes. The share of the population in each age and risk group
is available for the Netherlands.13 For the other two countries,
information at this level of detail with comparable risk
definitions was not available. In the absence of any evidence
for large differences in risk groups between countries, we used
the Dutch data for all three countries (table 1).
Vaccination efficacy
The vaccine was assumed to be an imperfect “all or nothing”
vaccine, such that with a certain probability it would provide
either perfect protection from infection or none at all (primary
vaccine failure). For ages 0-64 years we set the vaccine efficacy
(the probability that the vaccine would provide protection from
infection) at 80%. For those aged 65 or older, we assumed
vaccine efficacy to be 56%.14 We made no distinction for
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efficacy between people at high risk and low risk of serious
complications.
Evaluation of vaccination strategies in
different scenarios
Vaccination strategies
We investigated four alternative strategies for allocating the
available vaccines over the various age groups: firstly, not to
vaccinate; secondly, to offer vaccination to the whole
population; thirdly to vaccinate elderly people; and finally, to
vaccinate primary and secondary school children (ages 5-19),
so called high transmitters because these age groups have
relatively more contacts15 (see supplementary table A.1). Table
2⇓ shows the percentages of vaccine uptake used for each of
these strategies. Because for various reasons not all people
eligible for vaccination would be vaccinated, we chose a
vaccination coverage of at most 90% for everyone eligible for
vaccination. Because pandemic influenza vaccine is not
registered for infants under 6 months of age, the vaccination
percentage is lower for the age group 0-4 years (table 2).
Pandemic scenarios
To detect whether there was a single best vaccination strategy
for different countries under different circumstances, we
evaluated the four alternative strategies for four plausible
scenarios for an influenza pandemic.
In an optimistic scenario it is possible that a vaccine can be
produced against the new virus strain and that a large number
of vaccine doses would be available before the pandemic became
established (early vaccination). In a more pessimistic scenario
the same number of doses would become available during the
pandemic and vaccination would take place at the peak of the
pandemic (late vaccination). Simulations have shown that
availability of vaccines two weeks before the peak of the
pandemic or earlier give results similar to the early vaccination
scenario, and availability of vaccines later than twoweeks before
the peak give results similar to the late vaccination scenario.2
Because an influenza pandemic is caused by a novel virus strain,
it is possible that all those in the population are susceptible to
infection with the new virus strain before vaccination starts, the
so called “no immunity” scenario. As observations during the
Asian influenza pandemic16 and the recent pandemic in 200917
have shown, it is also possible for older people to have partial
cross immunity to the novel virus strain. We termed the
scenarios where some older people are protected from infection
at the start of the pandemic and before vaccination starts as
“pre-existing immunity.” The precise values of variables and
parameters in each of these scenarios are based on serological
studies during the 2009 influenza pandemic (table 3⇓).
Cost effectiveness
The cost per quality adjusted life year (QALY) gained was
calculated as the incremental cost effectiveness ratio of the
specific intervention strategy compared with the
non-intervention option. The incremental cost effectiveness
ratio represents the additional cost of one QALY gained and is
calculated as the difference in cost divided by the difference in
QALYs. A lower value for the incremental cost effectiveness
ratio indicates a more cost effective intervention. Often there is
no official threshold for when an intervention is considered to
be cost effective. In the United Kingdom, the National Institute
for Health and Clinical Excellence suggests a threshold range
of £20 000 (€24 786; $31 400) to £30 000.18 Here we apply the
higher of these (representing €37 800) for both the United
Kingdom and Germany. For the Netherlands no official
threshold exists, but €20 000 is mostly cited.19 20.
Healthcare use
It was assumed that 60% of the infected people developed
influenza-like illness and that the rest had no symptoms.21 22 A
proportion (25%) of those with symptoms seek medical help.
Several types of healthcare consumption were included in the
calculations: over-the-counter drug use, visits to a general
practitioner, prescription drugs (antibiotics to prevent or treat
secondary infections), and admissions to hospital in normal
wards (85%) and intensive care wards (15%).13 We assumed
that people with influenza-like illness received antiviral drugs
if in contact with a general practitioner, but we did not assume
any influence on transmission or complication rates. Rates of
hospital admission were based on Dutch data and were applied
to all three countries (see supplementary table A.2).23
Costs
From the published literature we obtained country specific data
on cost of using healthcare resources (direct costs) and
percentages of cases of influenza-like illness using the healthcare
resources (table 4⇓). When we could find no specific data for
Germany or the United Kingdom, we took data available for
the Netherlands as a proxy. This was the case for the direct cost
estimates of the percentages seeking medical help for
influenza-like illness, prescribed antibiotics during a visit to
their doctor, using over-the-counter drugs, and admitted to
intensive care. Some variation may be expected in these
proportions between the countries. However, the expectation is
that such variation would not be large enough to influence the
cost effectiveness ratios substantially. Vaccine costs are mainly
unknown and were based on unofficial sources. We assumed a
two dose schedule, and it was the same for all three countries.
According to the Dutch guidelines, costs for production losses
should be included in cost effectiveness analysis and estimated
using the friction costing approach.24 In the German guidelines,
the analyst’s perspective determines whether to include
production losses.25 According to the UK guidelines, all
important items should be included, and the inclusion of
production losses is not always required.26 We calculated all
costs with and without inclusion of production losses. For all
cases of influenza-like illness we used the friction cost method
for the Netherlands and the human capital approach for the other
two countries. The main differences between the two methods
is that the human capital approach estimates a potential value
of lost production due to absenteeism or death, whereas the
friction cost method suggests that the production losses might
be smaller. Owing to replacement of long term absent (or
deceased) employees and the assumption that short term
absenteeismwill be partly caught up with when sick employees
return to work, absent employees contribute to the production
losses only during the “friction period” until they are replaced.27
The difference between the magnitude of production losses
estimated with the two methods can be considerable when
estimating production losses due to deaths. To avoid the
exaggeration of differences in production losses between
countries owing to differences in methodology, we estimated
production losses due to deaths for all countries using the friction
cost method.
We recalculated all costs to reflect price levels in 2008. These
were expressed in euros using the average exchange rate between
the euro and the pound sterling over the year 2008. Costs were
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not discounted owing to the relatively short time perspective of
the analysis (within one year) on resource and financial impacts.
Quality of life and life years lost
Losses in quality of life due to an influenza episode were based
on burden of disease estimates for the Netherlands28 for the
scenario of no immunity. During the 2009 pandemic, estimates
of quality of life were gathered in the United Kingdom.7 We
used these weights for the scenario of pre-existing immunity,
reflecting the burden of illness due to the 2009 pandemic virus.
For cases admitted to hospital, the utility losses were 2.17 times
higher than for influenza-like illness7 (table 5⇓).
To estimate QALYs gained we based the remaining, age
specific, life years used in the economic calculations on country
specific demographic predictions for 2006 (table 1). These were
calculated with a weighting factor for the high and low risk
groups. The low risk group was weighted with a factor of 1.15
and the high risk group with a factor of 0.75, reflecting a longer
expected remaining lifetime for a healthy individual compared
with someone with chronic conditions.29We used the same case
fatality rate for all three countries, estimated as three age group
specific excess death rates due to influenza (see supplementary
table A.2).30 For the economic evaluation, we discounted life
years at country specific rates, according to the respective
guidelines: Germany at 5%, the Netherlands at 1.5%, and the
United Kingdom at 3.5%.
Sensitivity analysis
We explored the sensitivity of the health economic outcome for
uncertainty about the precise value of epidemic and economic
variables. Just as it is common practice to report the outcome
of data analysis as a point estimate with confidence intervals to
indicate the precision of this estimate, it is common to report
the projected incremental cost effectiveness ratios for a future
pandemic with a sensitivity analysis indicating the robustness
of this projection. We focused on five key variables.
The first key variable was the cost of the vaccine. We chose a
default value for unit costs of €10 and assessed the sensitivity
of the health economic outcome of doubling the unit cost of the
vaccine to €20, so called high costs. Other variables that affect
the costs of intervention would result in a similar sensitivity as
this cost of vaccination. The second key variable was the
discount rate for the life years gained. We lowered the discount
rates from the prescribed value for each country to zero (no
discounting). As a change in the discount rates results in a
different weighting of the number of life years gained, it also
assesses the sensitivity variables that affect the number of life
years gained.
The third key variable was the basic reproduction ratio, which
incorporates the effects of variations in transmissibility and
infectious period in one measure. We varied the basic
reproduction ratio from a default value of 1.7 to 1.55 (low
transmissibility) and 1.85 (high transmissibility). These low and
high values represented the two midpoints between the default
value, which we deemed most plausible, and the most extreme
values that are still consistent with observations of influenza
pandemics.2 5 31 The fourth key variable was vaccination
coverage. We varied the coverage from values in the base case
for each strategy (table 2) to half of these values (low
vaccination coverage). The fifth key variable was the level of
pre-existing immunity. We varied the level from values in the
base case (table 3) to a half higher than the base case (high
pre-existing immunity). Taken together, these epidemiological
variables span possible pandemics.
To explore potential interactions between the epidemiological
variables and health economic variables, we assessed the six
combinations of values for the basic reproduction ratio (1.55,
1.7, and 1.8) and vaccine costs (€10 unit costs, €20 unit costs).
Results
The clinical attack rate for an uncontrolled influenza pandemic
is similar for Germany, the Netherlands, and the United
Kingdom. The scenario where the total population is assumed
to be fully susceptible results in an overall clinical attack rate
of about 36%. When assuming pre-existing immunity in part
of the population, the overall clinical attack rate is about 27%.
Table 6⇓ shows the costs of vaccination, the difference in direct
healthcare costs (net direct costs), the difference in cost
including productivity losses (net total costs), and the QALY
gained for each vaccine availability for the different strategies.
The incremental cost effectiveness ratios for the vaccination
strategies are below country specific thresholds for all scenarios
for all three countries, and therefore all the interventions were
cost effective. For all three countries, all vaccination strategies
were more cost effective (that is, the incremental cost
effectiveness ratio was lower) in scenarios with no immunity
compared with scenarios with pre-existing immunity (table 6).
If production losses were included in the health economic
analysis, most vaccination strategies were cost saving for all
three countries. There were a few exceptions: in scenarios with
pre-existing immunity and in the scenario without immunity
and the vaccine being available late in the pandemic, vaccinating
elderly people was not cost saving for all three countries; in the
scenarios where the vaccine became available late in the
epidemic, vaccinating the whole population would not be cost
saving in the United Kingdom but would be in Germany and
the Netherlands.
In summary, the most cost effective vaccination strategy
depended on both the pandemic scenario and the country (table
7⇓). For instance, in the scenario without immunity and the
vaccine being available early in the pandemic, vaccinating
elderly people was the most cost effective strategy for Germany
(€940 per QALY gained), but vaccinating young people at
school (the high transmitters) was the most cost effective
strategy for the Netherlands (€525 per QALY gained) and the
United Kingdom (€163 per QALY gained, table 6).
To investigate why it would be most cost effective to vaccinate
young people at school rather than elderly people, two
vaccination strategies were looked at in more detail (vaccinating
elderly people and vaccinating high transmitters) for the
Netherlands and Germany, under the no immunity scenario.
The costs of vaccination and cost savings due to vaccination
(net direct costs) attributed to each age group as well as the
QALYs gained in that age group were calculated. The figure⇓
shows the results (costs per 10 000 population and QALYs
gained per 100 000 population). For the Netherlands, when high
transmitters were vaccinated the costs of vaccinating the age
groups 5-12 and 13-19 were higher than the costs saved in those
age groups, but because transmission was reduced the cost
savings and QALY gains in other age groups were large. The
cost savings in all groups, when taken together, were large
enough to make this the most cost effective strategy. This was
not so for Germany, where the costs saved and QALYs gained
in the age groups older than 20 did not compensate for the costs
in the vaccinated age groups (5-12 and 13-19). Compared with
the Netherlands it would be more cost effective for Germany
to vaccinate the older age group, where relatively more QALYs
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were gained. This difference remained when discounting was
omitted.
To assess the robustness of findings the key variables in the
analyses were varied (table 8⇓). In most of these analyses (with
the exception of Germany), vaccinating high transmitters was
the most cost effective option.With a low vaccination coverage
(half of the assumption in the base case) vaccinating the whole
population would be the most cost effective strategy for
Germany.
The influence of the relatively high discount rate used for the
QALYs in Germany on the incremental cost effectiveness ratios
(no immunity and early availability of vaccine) were
investigated. The incremental cost effectiveness ratio of
vaccinating high transmitters was about 9.4% higher than that
of vaccinating elderly people when the QALYs were not
discounted. When QALYs were discounted, the incremental
cost effectiveness ratio of vaccinating high transmitters was
about 8.8% higher than that of elderly people (comparing results
in table 6 with the sensitivity analysis “no discounting” reported
in supplementary table A.3). This suggests that the discount
rate does not determine the finding that vaccinating elderly
people first would be the most cost effective option.
Doubling the costs of the vaccine for each scenario did not
change the most cost effective strategy, and the most cost
effective strategy remained cost effective. Changing the basic
reproduction ratio to a lower value resulted in smaller epidemics.
This resulted in a few changes in the best vaccination
strategy—for example, in the scenario with early availability
of vaccine without pre-existing immunity, themost cost effective
strategy for Germany shifted from vaccinating elderly people
towards vaccinating high transmitters. Changing the basic
reproduction ratio to a higher value resulted in larger epidemics.
In the scenario with late availability of vaccine and pre-existing
immunity, the most cost effective strategy shifted for all three
countries from vaccinating high transmitters towards vaccinating
elderly people.
When the results of the sensitivity analyses were compared with
the base case including the productivity losses, the strategies
were no longer cost saving in several scenarios (see
supplementary tables A.3-A.5). For example, with higher
vaccine costs, vaccinating the whole population in Germany in
the late stage was no longer cost saving. In general, with more
pre-existing immunity all vaccination strategies became less
cost effective.
This suggests that the finding that the most cost effective
vaccination strategy depended on both the pandemic scenario
and the country was robust to the particular choice of variable
values.
Discussion
In this study we evaluated the cost effectiveness of four
vaccination strategies in Germany, the Netherlands, and the
United Kingdom, to find out which would be the most cost
effective for different influenza pandemic scenarios and if that
strategy differed among countries. The scenarios were no
vaccination, vaccinating elderly people, vaccinating high
transmitters, and vaccinating the whole population. The four
pandemic influenza scenarios were no immunity and vaccine
available either early or late and pre-existing immunity and
vaccine available either early or late. We found that the most
cost effective strategy differed between pandemic scenarios and
between countries. At the population level, all vaccination
strategies were cost effective (calculated as incremental cost
per QALY gained, comparing vaccination with no vaccination)
taking the country specific thresholds into account.
For all scenarios we found that vaccinating the whole population
was a suboptimal cost effective strategy. The most cost effective
strategy depended on both the scenario and the country. For
most scenarios we found that it would be most cost effective to
vaccinate young people aged 5-19 years (high transmitters).
The exceptions were that vaccinating elderly people was most
effective in a scenario without immunity and with the vaccine
becoming available late in the pandemic, in all countries. In
Germany, vaccinating elderly people would still be the most
cost effective strategy in the scenario without immunity and
when vaccine became available early in the pandemic. A
possible explanation for the discrepancy between optimal
strategies for Germany and the other two countries lies in the
age profile of the population. In Germany about 20% of the
population is 65 years or older, compared with about 14% in
the Netherlands and 16% in the United Kingdom. In general,
in the elderly age group a higher proportion are at a high risk
of complications.
We tested whether differences in demography can account for
the discrepancy in optimal vaccination strategies. We
re-evaluated the vaccination strategies for Germany with the
age profile of the German population replaced by that of the
Dutch population. For the scenario where vaccine was available
early and there was no pre-existing immunity, the most cost
effective strategy changed from vaccinating elderly people to
vaccinating high transmitters,. This confirms that the age profile
of the population can explain the observed discrepancy between
countries. We also evaluated the vaccination strategies for
Germany where we changed the cost structure of Germany to
that of the Netherlands. Again we found that the most cost
effective strategy changed from vaccinating elderly people to
vaccinating high transmitters. This stresses the need for country
specific analyses to determine themost cost effective vaccination
strategy, explicitly accounting for the country specific
demography and cost structure.
Strengths and weaknesses of the study
So far, no pandemic preparedness models of the cost
effectiveness of different vaccination strategies have
incorporated pre-existing immunity in elderly people or other
age groups. Since pre-existing immunity has played an important
part in the recent 2009 pandemic, we incorporated it in a
scenario for a future pandemic influenza virus strain. It might
have been expected that the role of pre-existing immunity would
make all vaccination strategies less cost effective. Here we
showed that pre-existing immunity leads to the strategy of
vaccinating high transmitters being optimal. It might also be
expected that the absence of pre-existing immunity would have
a larger impact on the cost effectiveness in a country where the
proportion of people in the older age groups is high, such as in
Germany. Indeed here we showed that for a population with a
high proportion of older people, in the absence of pre-existing
immunity, the strategy of vaccinating elderly people was
optimal.
Not all data were available for all three countries. We chose to
be conservative in our comparison between the countries and
to use the same data for all three countries. We used the data
from the Netherlands for the risk of being admitted to hospital,
the risk of death due to infection, and the distribution in risk
groups. Despite the conservative choices, we found that the
existing differences between the demographic characteristics,
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;345:e4445 doi: 10.1136/bmj.e4445 (Published 12 July 2012) Page 5 of 16
RESEARCH
especially the proportion of elderly people, suffice to result in
different optimal vaccination strategies between the countries.
Strengths andweaknesses in relation to other
studies
We did not attempt to calibrate the transmission model to the
recent pandemic A/H1N1 2009 influenza, as we did not seek
to generate the exact outcomes registered for this pandemic in
one specific country but rather to present a general analysis of
which strategy would be most cost effective in a future
pandemic. Vaccinating against the recent pandemic in the United
States showed that it was cost effective for several different
attack rates and for different age and risk groups according to
the estimations carried out using a decision analytical model.32
Some economic evaluations of vaccination strategies have also
been done during the recent pandemic using dynamic models.
In Ontario, Canada it was assumed that the vaccination coverage
was 30% within the population. It was shown that the
vaccination strategy was cost effective (<$C5000 per QALY
gained).33 In the United Kingdom, a transmission model was
fitted to the data from the recent pandemic. In that study, a
probabilistic economic model showed a high probability that
vaccinating high risk groups was cost effective; 98% of the
simulations resulted in an incremental cost effectiveness ratio
that was less than £30 000 per QALY gained.7Note that in these
simulations of the A/H1N1 pandemic the cost of the vaccine
was not included but instead regarded as a sunk cost. In our
analyses we included the cost of vaccination for a future
pandemic and hence the results of the health economic analyses
of the recent pandemic cannot be directly compared with our
health economic analyses of expected future pandemics.
Our analysis shows that the use of dynamic modelling is crucial
when studying a transmissible disease such as influenza. An
earlier study to determine the optimal strategy for distributing
a vaccine against a pandemic influenza virus used a static model
that did not take transmission into account.34 The option of
vaccinating children and young adults was then not even
considered. When vaccinating young people, the intervention
may not be cost effective if only the costs and effects in that
group are looked at, as we have shown (figure). Including effects
and cost savings at the population level changes the cost
effectiveness of the intervention, since other age groups benefit
from reduced transmission.We have added to the understanding
of this indirect benefit and shown that, in particular, it influences
cost effectiveness of pandemic vaccination strategies. This is
important information in making decisions on how to control
or mitigate an influenza pandemic.
Implications of study findings
Our primary objective was to compare the cost effectiveness of
vaccination strategies against an influenza pandemic for
countries with a similar cultural background, to examine the
usefulness of general advice on a vaccination strategy.
Since, compared with no vaccination, almost all vaccination
strategies were cost effective in almost all scenarios, the choice
of cost effective vaccination strategies is ample. Next to
considerations of cost effectiveness, decision makers should
factor in many other aspects, ranging from ethical considerations
to practical implementations. For example, vaccinating elderly
people is an attractive strategy since an existing infrastructure
for delivering seasonal influenza vaccination programmes can
be used to reach the target groups, whereas vaccinating high
transmitters requires a new infrastructure to reach this target
group, and the willingness to vaccinate might be lower among
these younger age groups.
We expect that the results may still hold even when decisions
are based on objectives other thanmaximising cost effectiveness.
This is relevant because a government also could choose to
minimise the number of infections, deaths, life years lost, or the
peak healthcare demand.Whereas in general a different objective
will result in a different optimal strategy, many simulations
have shown that in the control of infectious diseases different
objectives can result in similar optimal allocation patterns of
scarce vaccines.15 35 The intuition behind this result is that a
strategy that will break the transmission chain with theminimum
of effort will simultaneously minimise the number of infections,
deaths, life years lost, or peak healthcare demand and will
achieve a high cost effectiveness of infection control. Here,
vaccination of high transmitters usually is the strategy that could
break the transmission chain with minimal efforts—that is,
vaccine doses administered.
Unanswered questions and future research
We have not dealt with the ethical issues involved in vaccinating
younger age groups to protect older age groups, and we have
not tackled the risk of adverse events from vaccination. The
possible relation between the pandemic vaccine and the
occurrence of narcolepsy36 37 highlights that the ethical aspects
of a strategy where one group in the population carries the
potential risks of vaccination to protect another part of the
population should also be taken into consideration.
Conclusion
According to our analysis, no single vaccination strategy is most
cost effective across countries. There are, however, some general
rules. In most but not all scenarios, not vaccinating was the
worst strategy and vaccinating young people aged 5-19 years
was the most cost effective. Exceptions to this rule occurred
when vaccine became available early in the pandemic and there
was pre-existing immunity: depending on the proportion of
elderly people in the population, vaccinating elderly people was
the best strategy. These findings are of crucial importance for
the cost effectiveness of options to mitigate a future influenza
pandemic.We conclude that a general recommended vaccination
strategy should be considered with due caution. It makes sense
to advise about alternative strategies and to suggest preference
for one over another according to the particular country. One
such factor that countries may heed is the proportion of elderly
people in the population, which seems to determine which
strategy performs best.
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What is already known on this topic
Many countries have preparedness plans for pandemic influenza, specifying how vaccination should be prioritised if vaccine supply falls
short
Most countries have adapted their plans from other countries or from intergovernmental organisations such as WHO
Countries differ by demography, social contact patterns, healthcare systems, and cost structure of healthcare, and it is not known how
this affects the most cost effective strategy to prioritise pandemic influenza vaccine
What this study adds
Based on a mathematical model, the most cost effective strategy for pandemic influenza vaccination in Germany, the Netherlands, and
the United Kingdom would, with few exceptions, be to prioritise 5-19 year olds, the high transmitter group
With no pre-existing immunity and early vaccination, the optimal strategy differed between countries and was determined by the proportion
of elderly people in the population
General recommendations of a single strategy for a range of similar countries on how to prioritise pandemic influenza vaccines should
be considered cautiously
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Tables













0.8090.6970.4420.0160.0250.008% of population in high risk group†
10.436.358.373.381.788.9Remaining life years‡
*Total population: Germany 82 314 906; Netherlands 16 357 992; United Kingdom 60 587 800.
†Age group specific shares of population in high risk group based on Dutch data.13
‡Undiscounted projections from 2006, here calculated as averages in age group.39 40
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Table 3| Description of four scenarios for influenza pandemic








*Before peak of pandemic.
†Peak of pandemic.
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probability of useUnit cost (€)
Resource units or
probability of useUnit cost (€)
Resource units or
probability of useUnit cost (€)
Direct costs:
2 doses16*†2 doses16*†2 doses16*†Vaccine and administration
costs








—2892‡—339824—407541Episode of hospital stay
Production losses:
—118‡—21342—23341Per day, ages 20-40
—132‡—25542—23341Per day, ages 40-65
2.9‡—3.2542—2.1641—Days of absence, all ages
Dutch data are used when country specific data are missing. Prices updated to 2008 using country specific consumer price index.
*Per dose, including costs of administering drug.
†Assumed the same for all three countries.
‡Personal communication, K Tolley, 2008.
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Table 5| One year losses in quality of life due to influenza infection
Pandemic influenza
Seasonal influenzaInfection status Young people (<18 years)Adults
0.008270.007470.0128Influenza infection
0.01870.01670.02177Influenza infection with admission to hospital
Value of 1 represents death and value of 0 represents full health.
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Table 6| Results for cost effectiveness: vaccination costs, net direct costs, net total costs, quality adjusted life years (QALYs) gained, and
incremental cost effectiveness ratios (ICERs) comparing vaccination strategy with no vaccination for Germany, Netherlands, and United
Kingdom; price level 2008
ICER (cost/QALYs gained)




















































Net cost is difference in costs between vaccination strategy and no intervention (including costs of vaccination); net total cost includes indirect costs.
*Most cost effective strategy.
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Table 7| Overview of most cost effective vaccination strategy by country, vaccine availability, and immunity scenario
Pre-existing immunityNo immunityVariables
Germany:
High transmittersElderly peopleEarly vaccination
High transmittersElderly peopleLate vaccination
Netherlands:
High transmittersHigh transmittersEarly vaccination
High transmittersElderly peopleLate vaccination
United Kingdom:
High transmittersHigh transmittersEarly vaccination
High transmittersElderly peopleLate vaccination
Cost effectiveness is calculated using direct costs only. See table 6 for full results. Scenarios considered are no vaccination, vaccination of whole population,
vaccination of elderly people, and vaccination of high transmitters (young people aged 5-19 years). Table 2 provides an overview of scenarios.
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High transmittersHigh transmittersHigh transmittersHigh transmittersHigh transmittersElderly peopleEarly vaccination
High transmittersElderly peopleHigh transmittersElderly peopleHigh transmittersElderly peopleLate vaccination
No discounting:
High transmittersHigh transmittersHigh transmittersHigh transmittersHigh transmittersElderly peopleEarly vaccination
High transmittersElderly peopleHigh transmittersElderlyHigh transmittersElderly peopleLate vaccination
High transmissibility:
High transmittersHigh transmittersHigh transmittersHigh transmittersHigh transmittersElderly peopleEarly vaccination
Elderly peopleElderly peopleElderly peopleElderly peopleElderly peopleElderly peopleLate vaccination
Low transmissibility:
High transmitters*High transmitters*High transmittersHigh transmittersHigh transmittersHigh transmittersEarly vaccination
High transmittersElderly peopleHigh transmittersElderly peopleHigh transmittersElderly peopleLate vaccination
Low vaccination
coverage:
High transmittersHigh transmittersHigh transmittersHigh transmittersHigh transmittersWhole populationEarly vaccination
High transmittersElderly peopleHigh transmittersElderly peopleHigh transmittersElderly peopleLate vaccination
High pre-existing
immunity:
High transmittersNAHigh transmittersNAHigh transmittersNAEarly vaccination
High transmittersNAHigh transmittersNAHigh transmittersNALate vaccination
NA=not applicable.
Assumptions underlying sensitivity analyses are given in the methods. Supplementary tables A.4 to A.6 show the full sensitive results, including interactions
between factors, incremental cost effectiveness ratios, and scenarios with indirect costs. Cost effectiveness is calculated excluding indirect costs. Scenarios are:
vaccination of whole population, vaccination of elderly people, and vaccination of high transmitters—all compared with no vaccination. See table 2 for overview of
scenarios.
*Cost saving strategy.
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Figure
Incremental costs per 10 000 population and quality adjusted life years (QALYs) gained per 100 000 population, comparing
vaccinations strategies for elderly people and high transmitters (vaccine available early in pandemic, no immunity present)
for the Netherlands and Germany (direct healthcare costs (€), discounted (Germany 5%, Netherlands 1.5%) and without
discounting, price level 2008)
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